These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8827423)

  • 1. Epinephrine infusions in panic disorder: a double-blind placebo-controlled study.
    Veltman DJ; van Zijderveld GA; van Dyck R
    J Affect Disord; 1996 Jul; 39(2):133-40. PubMed ID: 8827423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients.
    Pols H; Verburg K; Hauzer R; Meijer J; Griez E
    Biol Psychiatry; 1996 Nov; 40(9):913-7. PubMed ID: 8896779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epinephrine and fear of bodily sensations in panic disorder and social phobia.
    Veltman DJ; van Zijderveld G; Tilders FJ; van Dyck R
    J Psychopharmacol; 1996 Jan; 10(4):259-65. PubMed ID: 22302971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptom specificity in patients with panic.
    Lelliott P; Bass C
    Br J Psychiatry; 1990 Oct; 157():593-7. PubMed ID: 2131141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular, respiratory, and panic reactions to epinephrine in panic disorder patients.
    van Zijderveld GA; TenVoorde BJ; Veltman DJ; van Doornen LJ; Orlebeke JF; van Dyck R; Tilders FJ
    Biol Psychiatry; 1997 Jan; 41(2):249-51. PubMed ID: 9018401
    [No Abstract]   [Full Text] [Related]  

  • 7. Interpretive bias for benign sensations in panic disorder with agoraphobia.
    Kamieniecki GW; Wade T; Tsourtos G
    J Anxiety Disord; 1997; 11(2):141-56. PubMed ID: 9168339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder.
    Lydiard RB; Lesser IM; Ballenger JC; Rubin RT; Laraia M; DuPont R
    J Clin Psychopharmacol; 1992 Apr; 12(2):96-103. PubMed ID: 1573046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictability, controllability, and fear of symptoms of anxiety in epinephrine-induced panic.
    Veltman DJ; van Zijderveld GA; van Dyck R; Bakker A
    Biol Psychiatry; 1998 Nov; 44(10):1017-26. PubMed ID: 9821566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring, trait anxiety, and panic disorder symptomatology in normal subjects.
    Muris P; Merckelbach H; Rassin E
    J Behav Ther Exp Psychiatry; 2000 Mar; 31(1):21-8. PubMed ID: 10983744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stressful reactions and panic attacks induced by flumazenil in chronic benzodiazepine users.
    Bernik MA; Gorenstein C; Vieira Filho AH
    J Psychopharmacol; 1998; 12(2):146-50. PubMed ID: 9694026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of intravenous diazepam pretreatment on lactate-induced panic.
    Liebowitz MR; Coplan JD; Martinez J; Fyer AJ; Dillon DJ; Campeas RB; Davies SO; Gorman JM; Klein DF
    Psychiatry Res; 1995 Sep; 58(2):127-38. PubMed ID: 8570764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consistencies between recalled panic and lactate-induced panic.
    Goetz RR; Klein DF; Gorman JM
    Anxiety; 1994; 1(1):31-6. PubMed ID: 9160544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An examination of levels of agoraphobic severity in panic disorder.
    Cox BJ; Endler NS; Swinson RP
    Behav Res Ther; 1995 Jan; 33(1):57-62. PubMed ID: 7872938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-infusion heart rates and laboratory-induced panic anxiety.
    Yeragani VK; Pohl R; Rainey JM; Balon R; Ortiz A; Lycaki H; Gershon S
    Acta Psychiatr Scand; 1987 Jan; 75(1):51-4. PubMed ID: 3554900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder.
    Benjamin J; Levine J; Fux M; Aviv A; Levy D; Belmaker RH
    Am J Psychiatry; 1995 Jul; 152(7):1084-6. PubMed ID: 7793450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group.
    Rosenbaum JF; Moroz G; Bowden CL
    J Clin Psychopharmacol; 1997 Oct; 17(5):390-400. PubMed ID: 9315990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognition-behaviour links in the persistence of panic.
    Salkovskis PM; Clark DM; Gelder MG
    Behav Res Ther; 1996; 34(5-6):453-8. PubMed ID: 8687367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the clinical utility of agoraphobia in the context of panic disorder.
    Schmidt NB; Cromer KR
    Depress Anxiety; 2008; 25(2):158-66. PubMed ID: 17351905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients.
    van Megen HJ; Westenberg HG; den Boer JA
    Biol Psychiatry; 1996 Oct; 40(8):804-6. PubMed ID: 8894076
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.